Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).

Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).

Accumulation and deposition of amyloid beta peptide (Abeta) within the mind causes neuronal apoptosis and finally results in Alzheimer’s illness (AD). A therapeutic goal for AD is to dam the cascade response induced by Abeta. It has been demonstrated that glucagon-like peptide-1 (GLP-1), which is an endogenous insulinotropic peptide secreted from the intestine, binds to its receptor within the mind and possesses neuroprotective results.
Utilizing site-directed mutagenesis and gene recombination strategies, we generated a mutated recombinant human glucagon-like peptide-1 (mGLP-1) which has longer half-life as in contrast with native GLP-1. This current work goals to look at whether or not mGLP-1 attenuates Abeta(1-42)-mediated cytotoxicity in SH-SY5Y cells and to discover the attainable mechanisms. Our information point out that>> or = 0.02 ng/ml of mGLP-1 facilitated cell proliferation and 0.1 ng/ml and 0.5 ng/ml of mGLP-1 rescued SH-SY5Y cells from Abeta(1-42)-induced apoptosis.
Furthermore, Abeta(1-42) remedy dramatically stimulated the discharge of Ca(2+) from inside calcium shops in SH-SY5Y cells, whereas mGLP-1 helped to take care of the intracellular Ca(2+) homeostasis. Abeta(1-42) additionally considerably elevated the expression degree of TP53 and Bax genes that are concerned in apoptotic pathways, and mGLP-1 decreased Abeta(1-42)-induced up-regulation of TP53 and Bax.
Since mGLP-1 remedy elevated cytosolic cAMP focus in SH-SY5Y cells, we postulate that mGLP-1 could exert its affect through binding to GLP-1 receptors in SH-SY5Y cells and stimulating the manufacturing of cAMP. These outcomes recommend that mGLP-1 exhibited neuronal safety properties, and will probably be a novel therapeutic agent for intervention in Alzheimer’s illness.

Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor.

Activation of the glucagon-like peptide-1 receptor (GLP-1R) upon ligand binding results in the discharge of insulin from pancreatic cells. This strictly glucose-dependent course of renders the receptor and its ligands helpful within the remedy of sort II diabetes mellitus. To allow a biophysical characterization in vitro, we expressed the human full-length GLP-1R within the cytosol of Escherichia coli as inclusion our bodies.
After purification, refolding of the SDS-solubilized receptor was achieved by the trade of SDS towards the detergent Brij78 utilizing a synthetic chaperone system. Far-UV round dichroism spectroscopic research revealed that the receptor adopts a attribute alpha-helical construction in Brij78 micelles. Ligand binding of the renatured protein was quantified by fluorescence quenching and floor plasmon resonance spectroscopy.
Within the presence of Brij micelles, the refolded receptor binds the agonist exendin-Four with an obvious dissociation fixed of roughly 100 nM in a reversible one-step mechanism. To exhibit that the detected ligand binding exercise isn’t solely attributable to an autonomously useful N-terminal area (nGLP-1R) but in addition attributable to extra contacts with the juxtamembrane half, we individually expressed and refolded the extracellular area counting on equivalent protocols established for the full-length GLP-1R.
In help of the urged multidomain binding mode, the nGLP-1R binds exendin-Four with a decrease affinity (Ok(app) within the micromolar vary) and a unique kinetic mechanism. The decrease ligand affinity of the nGLP-1R outcomes completely from a decreased kinetic stability of the receptor-ligand advanced, dissociation of which is roughly 40-fold quicker within the case of the nGLP-1R in comparison with the full-length GLP-1R.
In abstract, a framework was developed to supply useful human full-length GLP-1R by recombinant expression in E. coli as a prerequisite for eventual construction willpower and a rigorous biophysical characterization together with protein variants.

Results of low-dose recombinant human insulin-like development factor-I on insulin sensitivity, development hormone and glucagon ranges in younger adults with insulin-dependent diabetes mellitus.

Regardless of current curiosity within the therapeutic potential of recombinant human insulin-like development factor-I (rhIGF-I) within the remedy of diabetes mellitus, its mechanism of motion remains to be not outlined. We’ve studied the results of low-dose bolus subcutaneous rhIGF-I (40 microg/kg and 20 microg/kg) on insulin sensitivity, development hormone (GH) and glucagon ranges in seven younger adults with insulin-dependent diabetes mellitus (IDDM) utilizing a randomized double-blind placebo-controlled crossover research design.
Every was subjected to a euglycemic clamp (5 mmol/L) protocol consisting of a variable-rate insulin infusion clamp (6:00 PM to eight:00 AM) adopted by a two-dose hyperinsulinemic clamp (insulin infusion of 0.75 mU x kg(-1) x min(-1) from Eight to 10 AM and 1.5 mU x kg(-1) x min(-1) from 10 AM to 12 midday) incorporating [6,6 2H2]glucose tracer for willpower of glucose manufacturing/utilization charges.
Following rhIGF-I administration, the serum IGF-I degree (imply +/- SEM) elevated (40 microg/kg, 655 +/- 90 ng/mL, P < .001; 20 microg/kg, 472 +/- 67 ng/mL, P < .001; placebo, 258 +/- 51 ng/mL). Dose-related reductions in insulin have been noticed throughout the interval of steady-state euglycemia (1 AM to eight AM) (40 microg/kg, 48 +/- 5 pmol/L, P = .01; 20 microg/kg, 58 +/- Eight pmol/L, P = .03; placebo, 72 +/- Eight pmol/L). The imply in a single day GH degree (40 microg/kg, 9.1 +/- 1.Four mU/L, P = .04; 20 microg/kg, 9.6 +/- 2.Zero mU/L, P = .12; placebo, 11.3 +/- 1.7 mU/L) and GH pulse amplitude (40 microg/kg, 18.8 +/- 2.9 mU/L, P = .04; 20 microg/kg, 17.0 +/- 3.Four mU/L, P>> .05; placebo, 23.0 +/- 3.7 mU/L) have been additionally diminished. No variations in glucagon, IGF binding protein-1 (IGFBP-1), acetoacetate, or beta-hydroxybutyrate ranges have been discovered.
Throughout the hyperinsulinemic clamp circumstances, no variations in glucose utilization have been famous, whereas hepatic glucose manufacturing was diminished by rhIGF-I 40 microg/kg (P = .05). Our information exhibit that in topics with IDDM, low-dose subcutaneous rhIGF-I results in a dose-dependent discount within the insulin degree for euglycemia in a single day that parallels the lower in in a single day GH ranges, however glucagon and IGFBP-1 ranges stay unchanged.
The decreases in hepatic glucose manufacturing throughout the hyperinsulinemic clamp research noticed the next day are doubtless associated to GH suppression, though a direct impact by rhIGF-I can’t be completely discounted.

Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny.

Nuclear reprogramming of somatic tissue allows derivation of induced pluripotent stem (iPS) cells from an autologous, non-embryonic origin. The aim of this research was to ascertain environment friendly protocols for lineage specification of human iPS cells into useful glucose-responsive, insulin-producing progeny. We generated human iPS cells, which have been then guided with recombinant development elements that mimic the important signaling for pancreatic growth.
 Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).
Reprogrammed with 4 stemness elements, human fibroblasts have been right here transformed into genuine iPS cells. Underneath feeder-free circumstances, destiny specification was initiated with activin A and Wnt3a that triggered engagement into definitive endoderm, adopted by priming with fibroblast development issue 10 (FGF10) and KAAD-cyclopamine.
Addition of retinoic acid, boosted by the pancreatic endoderm inducer indolactam V (ILV), yielded pancreatic progenitors expressing pancreatic and duodenal homeobox 1 (PDX1), neurogenin 3 (NGN3) and neurogenic differentiation 1 (NEUROD1) markers. Additional steering, beneath insulin-like development issue 1 (IGF-1), hepatocyte development issue (HGF) and N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), was enhanced by glucagon-like peptide-1 (GLP-1) to generate islet-like cells that expressed pancreas-specific markers together with insulin and glucagon.

Recombinant (E.Coli) Human Glucagon

RP-589 100 ug
EUR 164

Recombinant Glucagon (GC)

4-RPB266Hu01
  • EUR 395.68
  • EUR 209.00
  • EUR 1208.80
  • EUR 469.60
  • EUR 839.20
  • EUR 328.00
  • EUR 2872.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P01275
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 21.9kDa
  • Isoelectric Point: Inquire
Description: Recombinant Human Glucagon expressed in: E.coli

Recombinant Glucagon (GC)

4-RPB266Mu01
  • EUR 440.48
  • EUR 221.00
  • EUR 1376.80
  • EUR 525.60
  • EUR 951.20
  • EUR 358.00
  • EUR 3292.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P55095
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 22.3kDa
  • Isoelectric Point: Inquire
Description: Recombinant Mouse Glucagon expressed in: E.coli

Recombinant Glucagon (GC)

4-RPB266Ra01
  • EUR 474.53
  • EUR 230.00
  • EUR 1504.48
  • EUR 568.16
  • EUR 1036.32
  • EUR 380.00
  • EUR 3611.20
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: P06883
  • Buffer composition: 100mMNaHCO3, 500mMNaCl, pH8.3, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 22.2kDa
  • Isoelectric Point: 6.1
Description: Recombinant Rat Glucagon expressed in: E.coli

Recombinant Human Glucagon, His Tag

7-02224 5µg Ask for price

Recombinant Human Glucagon, His Tag

7-02225 20µg Ask for price

Recombinant Human Glucagon, His Tag

7-02226 1mg Ask for price

Recombinant Human Glucagon/GCG (C-6His)

C664-10ug 10ug
EUR 202
Description: Supplied as a 0.2 μm filtered solution of 20mM TrisHCl,200mM NaCl,1mM DTT,50% Glycerol,pH 8.0.

Recombinant Human Glucagon/GCG (C-6His)

C664-1mg 1mg
EUR 2283
Description: Supplied as a 0.2 μm filtered solution of 20mM TrisHCl,200mM NaCl,1mM DTT,50% Glycerol,pH 8.0.

Recombinant Human Glucagon/GCG (C-6His)

C664-500ug 500ug
EUR 1613
Description: Supplied as a 0.2 μm filtered solution of 20mM TrisHCl,200mM NaCl,1mM DTT,50% Glycerol,pH 8.0.

Recombinant Human Glucagon/GCG (C-6His)

C664-50ug 50ug
EUR 496
Description: Supplied as a 0.2 μm filtered solution of 20mM TrisHCl,200mM NaCl,1mM DTT,50% Glycerol,pH 8.0.

Glucagon

7-02218 4mg Ask for price

Glucagon

7-02219 10mg Ask for price

Glucagon

7-02220 50mg Ask for price

Glucagon

HY-P0082 50mg
EUR 1069

Glucagon

MO15083 100 ug
EUR 383

Glucagon

RP-1507 4 mg
EUR 590

Human, Glucagon Human Recombinant Protein, His Tag

PROTP01275-5 Regular: 20ug
EUR 317
Description: Glucagon Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 112 amino acids (90-180 a.a.) and having a molecular mass of 12.8kDa.;Glucagon is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Human Glucagon (GCG)

1-CSB-EP009315HU
  • EUR 437.00
  • EUR 238.00
  • EUR 1544.00
  • EUR 653.00
  • EUR 1029.00
  • EUR 296.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 30.4 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Human Glucagon(GCG),partial expressed in E.coli

Human Glucagon (GCG)

1-CSB-EP009315HUc0
  • EUR 437.00
  • EUR 238.00
  • EUR 1544.00
  • EUR 653.00
  • EUR 1029.00
  • EUR 296.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 34.4 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Human Glucagon(GCG),partial expressed in E.coli

Human Glucagon (GCG)

1-CSB-RP089044h
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 31.4 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Human Glucagon(GCG),partial expressed in E.coli

Human Glucagon (GCG)

1-CSB-YP009315HU
  • EUR 430.00
  • EUR 234.00
  • EUR 1508.00
  • EUR 642.00
  • EUR 1009.00
  • EUR 291.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 6.4 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Human Glucagon(GCG),partial expressed in Yeast

Human Glucagon Peptide

20-abx260522
  • EUR 328.00
  • EUR 230.00
  • EUR 467.00
  • 0.5 mg
  • 100 ug
  • 1 mg
  • Shipped within 5-10 working days.

Glucagon Human protein

PROTP01275-4 Regular: 10mg
EUR 682
Description: Glucagon Human Synthetic is a single, non-glycosylated, polypeptide chain containing 29 amino acids and having a molecular mass of 3483 Dalton and the molecular formula is: C153H225N43O49S.;The Glucagon is purified by proprietary chromatographic techniques.

Recombinant human Glucagon-like peptide 1 receptor

P1282 100ug Ask for price
  • Uniprot ID: P43220
  • Reconstitution: Metal affinity chromatography on Fn Super Capacity Column (Nickel)
Description: Recombinant protein for human Glucagon-like peptide 1 receptor

Recombinant Human Glucagon Protein, GST, E.coli-100ug

QP8639-ec-100ug 100ug
EUR 408

Recombinant Human Glucagon Protein, GST, E.coli-10ug

QP8639-ec-10ug 10ug
EUR 200

Recombinant Human Glucagon Protein, GST, E.coli-1mg

QP8639-ec-1mg 1mg
EUR 1632

Recombinant Human Glucagon Protein, GST, E.coli-200ug

QP8639-ec-200ug 200ug
EUR 634

Recombinant Human Glucagon Protein, GST, E.coli-500ug

QP8639-ec-500ug 500ug
EUR 1060

Recombinant Human Glucagon Protein, GST, E.coli-50ug

QP8639-ec-50ug 50ug
EUR 263

Recombinant Human Glucagon Protein, His, Yeast-100ug

QP8639-ye-100ug 100ug
EUR 480

Recombinant Human Glucagon Protein, His, Yeast-10ug

QP8639-ye-10ug 10ug
EUR 236

Recombinant Human Glucagon Protein, His, Yeast-1mg

QP8639-ye-1mg 1mg
EUR 1885

Recombinant Human Glucagon Protein, His, Yeast-200ug

QP8639-ye-200ug 200ug
EUR 744

Recombinant Human Glucagon Protein, His, Yeast-500ug

QP8639-ye-500ug 500ug
EUR 1206

Recombinant Human Glucagon Protein, His, Yeast-50ug

QP8639-ye-50ug 50ug
EUR 299

Glucagon protein

30R-3141 50 ug
EUR 257
Description: Purified recombinant Glucagon protein

Glucagon antibody

20R-2537 250 uL
EUR 516
Description: Rabbit polyclonal Glucagon antibody

Glucagon antibody

70R-1710 100 ug
EUR 377
Description: Rabbit polyclonal Glucagon antibody raised against the N terminal of GCG

Glucagon antibody

70R-31205 100 ug
EUR 327
Description: Rabbit polyclonal Glucagon antibody

Glucagon Antibody

33385-100ul 100ul
EUR 252

Glucagon Antibody

33385-50ul 50ul
EUR 187

Glucagon Antibody

35510-100ul 100ul
EUR 390

Glucagon antibody

10-1794 200 ul
EUR 781
Description: Mouse monoclonal Glucagon antibody

Glucagon antibody

10-1795 200 ul
EUR 781
Description: Mouse monoclonal Glucagon antibody

Glucagon antibody

20-GR20 1 ml
EUR 192
Description: Rabbit polyclonal Glucagon antibody
Derived progeny demonstrated sustained expression of PDX1, and useful responsiveness to glucose problem secreting as much as 230 pM of C-peptide. A pancreatogenic cocktail enriched with ILV/GLP-1 affords a proficient means to specify human iPS cells into glucose-responsive hormone-producing progeny, refining the event of a personalised platform for islet-like cell technology.

Leave a Reply

Your email address will not be published. Required fields are marked *